If you want the shortest useful answer: insurance sometimes covers GLP-1 drugs for weight loss, but not reliably. Commercial plans still exclude obesity drugs surprisingly often. Medicare is opening a temporary bridge on July 1, 2026, but standard Part D rules still matter. Medicaid coverage for obesity remains optional by state. [3] [4] [5]

That means the question is not just “Is Wegovy covered?” It is:

  • Which plan do you have?
  • What diagnosis is your clinician using?
  • Does your plan cover obesity treatment at all?
  • Did the prior authorization packet match the drug’s approved use?

This guide is built for the person who already got the vague answer and needs the real one. If you want the full medication background first, start with our GLP-1 basics guide. If you are comparing access paths, also read our telehealth comparison, brand vs. compounded guide, and semaglutide guide.

The Actual Coverage Landscape in 2026

Employer plans: still the hardest place to get a clean yes

KFF’s 2025 Employer Health Benefits Survey found that only 19% of large firms offering health benefits covered GLP-1 drugs for weight loss. Coverage was more common among the very largest firms, but it was still not standard. KFF also reported that many employers adding coverage were using utilization controls such as prior authorization and lifestyle-program requirements. [1]

That number matters because employer plans cover most privately insured adults. So when people say, “insurance covers Wegovy now,” they are often projecting from a few generous plans, not the market as a whole.

The practical question to ask HR or the benefits broker is not “Do you cover GLP-1s?” Ask this instead:

“Did the plan exclude anti-obesity medications from the pharmacy benefit, or are Wegovy/Zepbound covered with prior authorization?”

Those are different problems. A prior authorization can be fixed. A benefit exclusion usually cannot.

ACA marketplace plans: coverage exists, but it is rare

Peterson-KFF Health System Tracker found that only 1% of HealthCare.gov marketplace plans covered Wegovy in 2024, and every plan that did cover it required prior authorization. [2]

That is a useful reality check. If you bought coverage on the ACA marketplace and your first answer was “excluded,” that is not unusual. It also means appeals work best when the problem is a mismatch between your diagnosis and the plan criteria, not when the marketplace product excludes obesity drugs entirely.

Medicare: expanding, but in stages

CMS says the Medicare GLP-1 Bridge runs from July 1, 2026 through December 31, 2026. It sits outside normal Part D payment flow and is designed as a temporary path before the longer BALANCE Model. CMS says eligible beneficiaries who meet the bridge criteria can access covered GLP-1 medications for obesity with a $50 monthly copayment. [3]

The second date to know is January 2027. CMS says the BALANCE Model is expected to begin for Medicare Part D then, while Medicaid participation can begin in May 2026. [4]

That does not mean standard Medicare suddenly covers every obesity prescription right now. The current Medicare rule still distinguishes between drugs used for obesity alone and drugs used for another FDA-approved indication that Medicare already covers. Wegovy is the clearest example: the FDA added an indication in March 2024 to reduce major cardiovascular events in adults with obesity or overweight and established cardiovascular disease. [6] Zepbound got an FDA approval in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. [7]

So if your clinician is prescribing for a covered indication such as cardiovascular risk reduction or sleep apnea, the insurance logic is different from a request framed only as weight loss.

Medicaid: still a patchwork, even with BALANCE coming

KFF reported that 13 state Medicaid programs covered GLP-1s for obesity treatment under fee-for-service as of January 2026, down from 16 in the 2025 survey. KFF also noted that when states do cover these drugs, they are usually subject to prior authorization and other utilization controls. [5]

The BALANCE Model could change the map, but it does not erase today’s reality. As of April 1, 2026, Medicaid obesity coverage is still optional at the state level. If you are on Medicaid, you need the current state preferred drug list and the current prior-authorization criteria, not a generic national answer. [4] [5]

The new variable: Foundayo

On April 1, 2026, Lilly announced FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Lilly describes it as an oral GLP-1 that can be taken without food or water restrictions and says commercial coverage may start at $25 per month, with self-pay starting at $149 per month. [9]

This is where precision matters. Lilly says eligible Medicare Part D patients may be able to get Foundayo for $50 per month beginning as soon as July 1, 2026. CMS’s Medicare GLP-1 Bridge page now matches that timing and says the bridge was updated on April 6, 2026 to include Foundayo, alongside Wegovy and Zepbound KwikPen, as bridge-eligible drugs. [3] [9]

So the fair read as of April 19, 2026 is this: Foundayo is now an FDA-approved obesity drug, and CMS has already added it to the Medicare GLP-1 Bridge for eligible beneficiaries starting July 1, 2026. That does not guarantee broader employer-plan or commercial formulary coverage on the same timeline. [3] [9]

What Prior Authorization Actually Means

A prior authorization is your insurer asking your prescriber to prove why the drug should be covered before the pharmacy claim pays. It is not a final denial. It is a paperwork gate.

Lilly’s current Zepbound prior-authorization guide is useful here because it lays out the same themes many plans use across the class. Plans may ask for:

  • current BMI
  • documentation of at least one weight-related comorbidity when BMI is 27 to under 30
  • confirmation that the medication will be used with diet and exercise
  • proof of prior weight-management attempts
  • current and past therapies
  • reauthorization evidence such as response to treatment or percentage of weight loss [12]

The FDA indication for Zepbound’s obesity use is also precise: adults with BMI 30 or greater, or BMI 27 or greater with at least one weight-related condition, alongside reduced-calorie diet and increased physical activity. [8] Foundayo uses similar BMI framing, according to Lilly’s April 1, 2026 release. [9]

That is why denials often happen. The plan is looking for a box to check, and the chart note never clearly says the patient met the FDA criteria.

Step-by-Step Prior Authorization Walkthrough

Step 1: Confirm the drug is not excluded

Before your clinician submits anything, confirm whether the plan:

  • covers the drug with prior authorization
  • covers a different GLP-1 but not the one you want
  • excludes obesity drugs entirely
  • only covers the drug for a different indication such as cardiovascular disease or sleep apnea

If the drug is excluded, the rest of the workflow changes. You are no longer arguing medical necessity inside a covered benefit. You are arguing for an exception or looking for another path.

Step 2: Match the diagnosis to the label

The request has to fit the exact FDA-approved indication. That means the clinician note should clearly document:

  • starting weight
  • current weight
  • starting BMI
  • current BMI
  • obesity-related conditions such as hypertension, dyslipidemia, sleep apnea, or cardiovascular disease
  • what lifestyle treatment has already been tried

If the indication is cardiovascular risk reduction with Wegovy or sleep apnea with Zepbound, the request should say that plainly and include the supporting diagnosis, not just “weight loss.” [6] [7]

Step 3: Build the packet before the prescription bounces

The strongest packet usually includes:

  • chart note with BMI and weight trend
  • medication list
  • diagnosis codes
  • documentation of supervised or clinician-documented weight-management effort
  • prior medication history if step therapy applies
  • a short clinician letter explaining why the requested product matches the label and the patient profile

Think of this as a mini legal packet, not a routine refill.

Step 4: Submit and track the timeline

Most plans respond in days to a few weeks, but the practical risk is not just insurer delay. It is incomplete paperwork causing a preventable denial, then a resubmission, then another queue.

The useful move here is simple: once the PA is submitted, ask the office for three specifics:

  1. The submission date.
  2. The exact diagnosis used.
  3. Whether chart notes and prior weight-management history were attached.

If the office cannot answer those three questions, you do not actually know what was sent.

Step 5: If denied, get the denial reason in writing

Do not appeal a vague denial. Ask for the exact reason first. Common examples:

  • obesity-drug exclusion
  • BMI criteria not met
  • missing comorbidity documentation
  • step therapy not completed
  • inadequate documentation of lifestyle intervention
  • non-covered diagnosis coding

Each denial reason leads to a different fix.

What Your Prescriber Should Send

If your clinician wants the cleanest possible first submission, this is the checklist:

  • BMI at treatment start and current BMI
  • exact obesity-related diagnoses and supporting chart history
  • blood pressure, lipids, sleep study, or cardiovascular history if relevant
  • prior weight-management work, even if it was not a formal commercial program
  • previous anti-obesity medications and why they were ineffective or not tolerated
  • language tying the request to the drug’s FDA-approved indication
  • the plan’s own PA form, completed fully

NovoCare’s sample Wegovy coverage request letter is useful because it reinforces the same practical point: the medical-necessity letter should read like a coverage argument, not a generic office note. [13]

Copyable Insurance Appeal Letter Template

Use this when the drug is a covered benefit but the first prior authorization was denied. Edit the bracketed sections so the facts are true.

[Date]

RE: Internal Appeal for [Drug Name]
Patient: [Full Name]
DOB: [DOB]
Member ID: [ID]
Claim / Reference Number: [Number]

To the Medical Review Team:

I am appealing the denial of coverage for [Drug Name] for [Patient Name]. This request meets the drug's FDA-approved indication and the patient's documented clinical needs.

Clinical summary:
- Current BMI: [BMI]
- Starting weight: [Weight]
- Current weight: [Weight]
- Relevant diagnoses: [obesity, hypertension, dyslipidemia, obstructive sleep apnea, established cardiovascular disease, etc.]
- Previous weight-management efforts: [nutrition counseling, structured program, exercise program, prior anti-obesity medication trial, dates if available]

[Patient Name] meets the labeled criteria for [Drug Name] because [state the exact indication clearly].

This request is medically necessary because:
1. The patient has obesity or overweight with clinically significant weight-related disease.
2. Lower-cost or preferred alternatives are [not appropriate / not tolerated / contraindicated / already tried], specifically: [details].
3. Delaying treatment is likely to worsen [comorbidity], increase long-term health risk, and conflict with evidence-based obesity care.

Attached documentation includes:
- recent chart notes
- BMI and weight history
- problem list and medication list
- prior treatment history
- supporting test results where relevant

Please reconsider this denial based on the patient's documented clinical status and the drug's FDA-approved use.

Sincerely,
[Clinician name, credentials, NPI]

The two phrases that usually matter most are:

  • “meets the FDA-approved indication”
  • “the denial conflicts with the plan’s published criteria”

That is the language insurers respond to. Not emotional language. Not “the patient really wants this drug.”

What To Do If Insurance Denies the Request

1. File the internal appeal first

HealthCare.gov says you generally have 180 days after the denial to file an internal appeal. The insurer usually must respond within 30 days for a service you have not yet received or 60 days for a service you already received. [10]

2. Use external review if the insurer still says no

After a final internal denial, HealthCare.gov says you generally have 4 months to request external review. Standard external review decisions are generally due within 45 days, while expedited review can move within 72 hours if the medical situation is urgent. [11]

3. Escalate to the state consumer help channel when appropriate

HealthCare.gov says state Consumer Assistance Programs or the state Department of Insurance can help with appeals and external review questions. [10] [11]

That is worth doing when the denial looks inconsistent with the plan language, not just when you are frustrated.

If Coverage Is Excluded Entirely

This is the hard version of the problem. If the employer plan or marketplace plan excludes obesity drugs, the appeal path is weaker because the insurer is not saying you failed medical necessity. It is saying the benefit is not there.

At that point your realistic options are:

  • ask whether the drug is covered for a different FDA-approved indication you actually have
  • ask HR whether the employer will revisit the exclusion at renewal
  • compare cash-pay or telehealth options in our GLP-1 telehealth comparison
  • compare branded vs. non-branded access routes in our brand vs. compounded guide
  • ask about manufacturer programs and current official savings terms

Foundayo is the newest example of why this category may move quickly over the next year. A daily oral option changes the market story, but it does not guarantee that your plan will add coverage on your timeline. [9]

Bottom Line

The real answer in 2026 is not “insurance covers GLP-1s” or “insurance never covers GLP-1s.” It is more specific:

  • employer coverage is still limited
  • ACA marketplace coverage is rare
  • Medicare obesity access is expanding in dated phases
  • Medicaid remains state-by-state
  • most winnable denials are documentation problems

If you are about to start this process, the best move is to slow down for one hour and build the packet correctly before the first submission. That means BMI, diagnoses, prior treatment history, and a clinician letter tied to the exact FDA-approved indication. That boring paperwork is often the difference between a fast approval and a three-month loop.

If you want the coverage changes worth paying attention to without tracking every CMS memo yourself, join the newsletter. We send the policy shifts, pricing changes, and access updates that actually change what patients can do next.